JENBURKT Jenburkt Pharmaceuticals Limited

Regd. Office: 93, Jayprakash Road, Andheri (West), Mumbai - 400 058. Phone: 022-67 603 603 Fax: 91-22-66943127

Ref. No. JPL/CS/2233/2025 Date: 12th August, 2025.

To
BSE Ltd.
P.J. Towers, Dalal Street,
Mumbai - 400 001.
Script Code : **524731**

Sub.: Outcome of Board Meeting held today, i.e. 12th August, 2025 - standalone Unaudited Financial Results of the Company for the Quarter ended on 30th June, 2025.

Reg.: Regulation 30(2) and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.

Dear Sir,

Kindly note that the Audit Committee have reviewed and the Board of Directors of the Company have approved the standalone unaudited financial results of the Company for the quarter from 1st April, 2025 to 30th June, 2025, during their respective meetings held today, i.e. on 12th August, 2025.

The said standalone unaudited financial results for the quarter from 1st April, 2025 to 30th June, 2025, duly signed in the format specified under regulation 33(4) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, is enclosed.

Also, enclosed alongwith is the limited audit review report of the auditors of the Company, on the standalone unaudited financial results for the quarter ended on 30th June, 2024.

The Board Meeting commenced at 02.30 p.m. (IST) and concluded at 5:15 p.m. (IST) on 12th August, 2025.

Kindly take on record the above and acknowledge.

Thanking you,

Yours faithfully,
For Jenburkt Pharmaceuticals Limited,

(ASHISH R. SHAH)
Company Secretary and Compliance Officer

JENBURKT Jenburkt Pharmaceuticals Limited

Regd. Office: 93, Jayprakash Road, Andheri (West), Mumbai - 400 058. Phone: 022-67 603 603 Fax: 91-22-66943127

Statement of Standalone Unaudited Financial Results for the Quarter Ended on 30th June, 2025

(Rs. in Lacs other than EPS)

			Particulars	Quarter Ended			Year Ended
				30-06-2025	31-03-2025	30-06-2024	31-03-2025
				Unaudited	Audited	Unaudited	Audited
I			Revenue from Operations	3552.68	4104.69	3253.57	15169.15
II			Other Income	205.71	188.02	140.57	672.10
III			**Total income (I + II)**	**3758.39**	**4292.71**	**3394.14**	**15841.25**
IV			Expenses				
		(a)	Cost of Materials Consumed	213.54	228.48	183.77	851.12
		(b)	Purchase of Stock-in-trade	537.24	524.61	575.23	2126.08
		(c)	Changes in inventories of Finished Goods, Stock-in-trade and WIP	-99.02	37.16	-130.00	-11.55
		(d)	Employee benefit expenses	1172.08	1143.35	1066.75	4553.58
		(e)	Finance Costs	10.99	11.13	11.48	45.28
		(f)	Depreciation and Amortisation Expense	72.25	79.13	51.90	272.79
		(g)	Other expenses	833.11	1085.31	628.88	3610.67
			Total Expenses (IV)	**2740.19**	**3109.17**	**2388.01**	**11447.97**
V			**Profit before tax (III - IV)**	**1018.20**	**1183.54**	**1006.13**	**4393.28**
VI			Tax Expense				
		(i)	Current Tax	200.00	340.00	250.00	1190.00
		(ii)	Income Tax for previous years	0.00	17.80	0.00	17.80
		(iii)	Deferred Tax	39.02	-27.92	14.53	-20.58
VII			**Profit after tax for the period (V-VI)**	**779.18**	**853.66**	**741.60**	**3206.06**
VIII			Other Comprehensive Income				
A	A	(i)	Items that will not be reclassified to profit or loss	155.19	-49.98	173.60	136.06
		(ii)	Income Tax relatiing to Items that will not be reclassified to profit or loss	-17.76	4.83	-18.52	16.80
B	B	(i)	Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00
.		(ii)	Income Tax relatiing to Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00
IX			**Total Comprehensive Income for the period (VII + VIII)**	**916.61**	**808.51**	**896.68**	**3358.92**
			Paid up Equity Share Capital (F.V. Rs.10/- each)	**441.33**	**441.33**	**441.33**	**441.33**
X			**Earnings Per Share (in Rs.) (F.V. Rs.10/-) Basic and Diluted ***	**17.66**	**19.34**	**16.80**	**72.65**

Notes:

1 The above statement of standalone unaudited financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 12th August 2025.

2 The Company is dealing exclusively in Pharmaceuticals business segment, hence segment wise reporting is not applicable.

For Jenburkt Pharmaceuticals Ltd.

JENBURKT PHARMACEUTICALS LTD. (MUMBAI)

(Ashish U. Bhuta)
Chairman & Managing Director
(DIN No: 00226479)

Place : Mumbai
Date : 12th August 2025

D.R.MEHTA & ASSOCIATES

(CHARTERED ACCOUNTANTS)

H-2, EVEREST BUILDING, 9TH FLOOR, TARDEO CIRCLE, MUMBAI - 400034
TEL: 23513758 / 23520330 FAX: 66607263, 9322508373
Email ID: info@drmehta.in, vikram@drmehta.in, ashok@drmehta.in

Limited Review Report on Unaudited Quarterly Standalone Financial Results of Jenburkt Pharmaceuticals Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015

To the Board of Directors of

Jenburkt Pharmaceuticals Limited

We have reviewed the accompanying statement of unaudited standalone financial results of JENBURKT PHARMACEUTICALS LTD for the quarter ended 30th June 2025 (the statement).

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of this matter.

For D.R.Mehta & Associates,
Chartered Accountants
(Firm Reg. No. 106207W)

D.R. MEHTA & ASSOCIATES * CHARTERED ACCOUNTANTS * M. NO. 106207W MUMBAI

Partner
Vikram Mehta
(Membership No. 47347)
UDIN: **25047347BMKQGI8039**
Place: Mumbai
Date: 12th August 2025